Skip to content

Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance

Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01361971
Acronym
HOTAIR
Enrollment
20
Registered
2011-05-27
Start date
2011-04-30
Completion date
2013-01-31
Last updated
2013-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Type 2 Diabetes

Keywords

Insulin resistance, Inflammation, Hypoxia

Brief summary

Obesity is an epidemic in Western society and is the biggest risk factor for insulin resistance and type 2 diabetes. The investigators have preliminary evidence showing that hyperbaric oxygen therapy rapidly increases insulin sensitivity in humans. This requires confirmation in a larger population, and with this study the investigators will also test for mechanisms how this occurs. The investigators suspect that modulation of hypoxia and stress response proteins following changes in tissue oxygenation may contribute to these improvements. This study has the potential to yield new and important insights into the insulin resistance in obesity.

Interventions

Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.

Sponsors

University of Adelaide
Lead SponsorOTHER

Study design

Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
45 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Obese men with and without type 2 diabetes aged 45-70 * Lean men without type 2 diabetes aged 45-70

Exclusion criteria

* smokers * claustrophobic * sleep apnoea * blood donor * exercise more than 2 times per week * under certain medications eg: bleomycin,corticosteroid

Design outcomes

Primary

MeasureTime frameDescription
Insulin sensitivity1 yearUsing Hyperinsulinemic clamp

Secondary

MeasureTime frameDescription
Hypoxia and inflammatory markers1 yearusing IHC, qPCR, Western blot

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026